← 返回

鉴定并验证 Birc5 作为肝细胞癌中与免疫抑制性髓源性抑制细胞浸润相关的新型活化细胞周期程序生物标志物

英文原题:Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.

查看英文原题

Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.

PubMed 2023/06/16(内容时间) Cancer Med Q2 · IF 3.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

Birc5 是 MDSC 瘤内浸润的潜在生物标志物和诱导因子,导致肿瘤免疫微环境中 T 细胞排斥或功能障碍,从而使 HCC 对 ICIs 的应答降低。

研究思路结论见上方概要

临床前研究和临床试验已证明,肿瘤内在的细胞周期程序激活会阻碍抗癌免疫治疗。识别细胞周期相关生物标志物可能为增强肝细胞癌(HCC)免疫治疗疗效提供新的治疗靶点。方法与结果:基于与细胞周期程序相关的基因,通过非负矩阵分解算法在HCC患者中检测到两个聚类(Cluster 1和Cluster 2)。多变量调整的Cox回归分析表明,基于细胞周期基因的分类是预测HCC患者临床结局的重要预后因素。Cluster 1显示较短的总生存时间和无进展间期时间,与激活的细胞周期程序、更高的髓源性抑制细胞(MDSCs)浸润以及对免疫治疗较低的敏感性相关。构建了一个包含BIRC5、C8G和SPP1的三基因预后模型,用于表征HCC基于细胞周期的分类,该模型具有强稳健性和稳定的预测性能。值得注意的是,Birc5与HCC组织中CD11b表达(一种MDSC标志物)呈正相关。Birc5高表达与MDSCs瘤内浸润水平一致,均与HCC患者更差的预后相关。在体外,肝细胞Birc5过表达促进人外周血单个核细胞中免疫抑制性CD11b + CD33 + HLA-DR - MDSC扩增。基因修饰的肝癌动物模型显示,Birc5缺失上调了与淋巴细胞介导免疫、NK 细胞介导免疫、干扰素-γ产生、T细胞激活和T细胞介导细胞毒性相关的基因。这些结果表明Birc5在HCC中具有免疫抑制功能。

展开英文摘要原文

Preclinical studies and clinical trials have demonstrated that tumor-intrinsic activation of the cell cycle program impedes anticancer immunotherapy. Identification of cell cycle-related biomarkers may provide novel therapeutic targets to augment the efficacy of immunotherapy in hepatocellular carcinoma (HCC). METHOD AND RESULTS: Based on the genes related to cell cycle program, two clusters (Cluster 1 and Cluster 2) were detected in HCC patients via non-negative matrix factorization algorithm. Multivariable-adjusted Cox regression analysis indicated that the cell cycle gene-based classification was a significant prognostic factor for predicting the clinical outcome of HCC patients. Cluster 1 showed shorter overall survival time and progression-free interval time was associated with activated cell cycle program, higher infiltration of myeloid-derived suppressor cells (MDSCs) and less sensitivity to immunotherapy. A three-gene prognostic model, including BIRC5, C8G, and SPP1, was constructed to characterize the cell cycle-based classification of HCC, which had strong robustness and a stable predictive performance. Notably, Birc5 was positively correlated with CD11b expression (a MDSC marker) in HCC tissue. Concordant high expression of Birc5 and intratumor infiltration level of MDSCs were correlated with worse prognosis of HCC patients. In vitro, hepatocellular Birc5 overexpression promoted immunosuppressive CD11b + CD33 + HLA-DR - MDSC expansion from human peripheral blood mononuclear cells. Genetically modified animal model of liver cancer revealed that Birc5 depletion upregulated the genes related to lymphocyte-mediated immunity, natural killer cell-mediated immunity, interferon-gamma production, T-cell activation, and T-cell-mediated cytotoxicity. These results suggest an immunosuppressive function of Birc5 in HCC.

Birc5 was a potential biomarker and inducer of intratumor infiltration of MDSCs, which led to T cell exclusion or dysfunction in tumor immune microenvironment, consequently resulting in reduced response to ICIs in HCC.

论文信息

作者
Liu Y、Chen X、Luo W、Zhao Y、Nashan B、Huang L、Yuan X
第一作者单位
Department of Radiation Oncology, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.China
通讯作者单位
Organ Transplant Center, Department of Hepatobiliary and Transplantation Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.China
文献类型
非美国政府资助研究
期刊
Cancer medicine2023 Aug
原文标识
PubMed 37326143 · DOI 10.1002/cam4.6271